We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Abingdon Health Plc | ABDX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.67 | 9.12% | 8.02 | 16:35:17 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.35 | 7.35 | 7.80 | 8.02 | 7.35 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 17/5/2024 12:20 by z1co Proactive Investors:Abingdon Health CEO discusses strong interim results, robust pipeline and growth strategy Published: 10:38 15 Mar 2024 GMT Yates said a 117% revenue increase to £2.4 million during the interim period was primarily driven by its CDMO division. This growth was attributed to increases in development, operational revenues, and the emergence of regulatory area revenues. Despite an inflationary environment, Abingdon Health managed to maintain stable operating costs, resulting in improved gross margins to over 50%. The company has a robust opportunity pipeline with 29 ongoing projects, emphasizing its fully integrated solution's appeal to customers. Yates also highlighted a good start to the second half of the year, with revenues expected to grow significantly while controlling costs to enhance operating profit performance. |
Posted at 15/3/2024 15:26 by daz TimboI thought the outlook statement was very misleading. Last year ABDX had a strong H2 weighting and it looks to be the same this year, so to say H2 will be materially ahead of H1 is meaningless. A comparison with H2 last year would have given investors a much better insight. Growth will not be 116% in H2 but I want to know 1. Will it be positive and 2. If positive, by roughly how much 20/30/40% etc. Also, the cash outflow in H1 was £1.238m and they only have £2m cash left. While the burn rate will be lower in H2, without better guidance, it becomes impossible for private investors to make an informed view on the H2 outflow. No doubt Brokers will have been greater insight but it's not much help to me. Based on the lack of clarity, I can't dismiss the need for another fund raise. |
Posted at 20/6/2023 18:51 by criticalthinker1 Someone needs to tell boomboom on lse that we have the rights to UK and Ireland, not globally. That's good enough for me. A piece of a cake is better than no cake. Especially given its usp!The added extra to the Salistick launch is the media attention Abingdon get as a company. Their other pipelines will garner awareness, and if I was a buyer for a large organisation it would give myself/bosses/invest I'm sure others have noticed the tyre kickers are apparent on lse...just a little kick down, here and there, it's so obvious, just a kick and no ...but this has potential based on ...which thankfully muck on lse politely kicks them into the verge with facts. Much more to come here. |
Posted at 25/11/2022 07:13 by shallow pockets We obtained our long held secondary short target of 4p (well, 4.16p) yesterday. Anyone other than BigJock 36 (aka Tiny and Broke) and his bull mates has done well. Top investors always focus on the quality of management as an investment criteria. Abingdon's is as poor as it gets, unqualified for the job, with a CEO with no discernible track record of any success nor competence as a CEO in our opinion. How could this Board have not done well in the greatest opportunity that was presented to them in the Covid pandemic? Its a disastrous management performance.What is striking is the lack of any bounce derived from a lack of takeover rumours. But why would anyone buy it? They have no assets of any second hand value other than the last dregs of cash, continuing to dwindle as the Board remunerate themselves and fund their lifestyles as the company moves towards liquidation. They don't own their building. Their kit has minimal resale value. They have no IP value. They have nothing. There will be no further significant fund raises. Tick, tick tick.....goodbye Abingdon. RIP. |
Posted at 02/3/2022 09:37 by shallow pockets This morning our target of 8p got hit. We are NOT covering our shorts just yet. There is more price downside here, as cash drains daily, no investors are in sight, and the next secular phase of medical/health testing is 6 months or more away. Management seem devoid of ideas or a strategy and no one is accepting responsibility for this share price destruction. Viewing a contested Government debt as an asset could even appear delusional, especially with this Government. Stay short. |
Posted at 15/2/2022 14:57 by shallow pockets Don't hold your breath, Inv. This stock is just not bouncing from its lows. Why would it? Heavy on overhead. Heavy on capex. Starving of both product and income. No investors waiting outside the front door. And Omega's firesale of one of its factories probably values ABDX assets at as little as half of the current value. "Cheap" (based on previous over valuation due to the pandemic) can get cheaper because it wasn't cheap in the first place. Just over valued.Target is 8p. Stay short. Sell bounces. No good news on the horizon. |
Posted at 02/2/2022 09:49 by shallow pockets So, we are through and beyond our price target of 18 in the death spiral of this share. There is now a phase of shock and awe with the sticker price. Those who have held on despite our warnings now think it's too low to bother selling out, as does management who will resist any new investors at what they consider to be a too low/artificial share price. But the lack of any bounce in the days to come, and the absence of the Board in bringing in new money at the current share price will lead to continued price drift shortly as everyone gets used to the new normal in this hare price valuation. Any new money out there smells blood and death. Their choice is to deal with a liquidator in bankruptcy or to provide a bailout at about 5p. There is unlikely to be any other outcome. New pre-ordered equipment is due to be delivered soon which will further drain existing capital. Hold on tight. |
Posted at 09/12/2021 22:02 by master rsi At Market Report"Although the EU medicines watchdog said Omicron may cause milder disease, investors were mindful of a Japanese study which suggested the variant could be over four times more contagious. Bloomberg on Thursday reported findings from a study performed by Hiroshi Nishiura, a Japanese scientist, which suggested the new variant could be 4.2 times more transmissible in its early stage than Delta." |
Posted at 01/12/2021 12:48 by david gruen It's not as fast as the OCTP train:"We are delighted to see the commencement of dual trading in the Company's shares today, marking another significant corporate milestone for OTCP. It will increase liquidity and significantly enhance the ability of US-based investors to access and trade OCTP shares. In the coming months, OCTP's management team will be placing additional emphasis upon increasing our outreach efforts to US-based institutional and retail investors and widening our shareholder base." |
Posted at 01/12/2021 09:57 by bad robot I will be closing my shorts here at 2p by February/MarchAbout 1m opex per month, then bonus. The placement is most geared to the people who put money in the IPO, locked in the period in December. Expect a massive sell-off. Giro investors should pack their bags. BR IN BR WE TRUST RED MERCURY CREW |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
